Condor Capital Management Sells 153 Shares of Agilent Technologies, Inc. (NYSE:A)

Condor Capital Management trimmed its holdings in Agilent Technologies, Inc. (NYSE:A) by 1.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,636 shares of the medical research company’s stock after selling 153 shares during the quarter. Condor Capital Management’s holdings in Agilent Technologies were worth $1,563,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Vestal Point Capital LP bought a new stake in shares of Agilent Technologies in the third quarter valued at approximately $14,848,000. Sienna Gestion boosted its position in shares of Agilent Technologies by 29.8% in the fourth quarter. Sienna Gestion now owns 78,445 shares of the medical research company’s stock valued at $10,537,000 after acquiring an additional 17,991 shares during the period. S.E.E.D. Planning Group LLC boosted its position in shares of Agilent Technologies by 12.7% in the fourth quarter. S.E.E.D. Planning Group LLC now owns 42,587 shares of the medical research company’s stock valued at $5,721,000 after acquiring an additional 4,805 shares during the period. Sequoia Financial Advisors LLC lifted its position in Agilent Technologies by 8.5% in the fourth quarter. Sequoia Financial Advisors LLC now owns 33,898 shares of the medical research company’s stock worth $4,554,000 after purchasing an additional 2,664 shares during the period. Finally, Miracle Mile Advisors LLC bought a new position in Agilent Technologies in the fourth quarter worth $362,000.

Agilent Technologies Stock Performance

Shares of NYSE:A opened at $122.27 on Thursday. Agilent Technologies, Inc. has a twelve month low of $117.17 and a twelve month high of $155.35. The firm has a market cap of $34.86 billion, a PE ratio of 28.11, a price-to-earnings-growth ratio of 3.45 and a beta of 1.11. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.66 and a current ratio of 2.20. The business has a fifty day moving average of $137.41 and a 200-day moving average of $137.57.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. The company had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. On average, equities research analysts predict that Agilent Technologies, Inc. will post 5.57 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be given a $0.248 dividend. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a yield of 0.81%. Agilent Technologies’s payout ratio is 22.76%.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the transaction, the chief executive officer now owns 39,652 shares in the company, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Rodney Gonsalves sold 1,908 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $121.98, for a total value of $232,737.84. Following the transaction, the vice president now owns 21,786 shares in the company, valued at approximately $2,657,456.28. This trade represents a 8.05 % decrease in their position. The disclosure for this sale can be found here.

Analysts Set New Price Targets

Several research analysts recently commented on A shares. JPMorgan Chase & Co. reduced their target price on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research report on Tuesday, November 26th. Wells Fargo & Company reduced their target price on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a research report on Monday, December 9th. Citigroup raised their target price on Agilent Technologies to $165.00 and gave the stock a “buy” rating in a research report on Thursday, December 19th. StockNews.com raised Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Finally, Robert W. Baird dropped their price objective on Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. Seven investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $146.15.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.